The ABCG2 multidrug transporter is a pump gated by a valve and an extracellular lid.
Narakorn KhunweeraphongDaniel SzöllősiThomas StocknerKarl KuchlerPublished in: Nature communications (2019)
The human ATP-binding cassette transporter ABCG2 is a key to anticancer resistance and physiological detoxification. However, the molecular mechanism of substrate transport remains enigmatic. A hydrophobic di-leucine motif in the ABCG2 core separates a large intracellular cavity from a smaller upper cavity. We show that the di-leucine motif acts as a valve that controls drug extrusion. Moreover, the extracellular structure engages the re-entry helix and all extracellular loops to form a roof architecture on top of the upper cavity. Disulfide bridges and a salt bridge limit roof flexibility, but provide a lid-like function to control drug release. We propose that drug translocation from the central to the upper cavities through the valve is driven by a squeezing motion, suggesting that ABCG2 operates similar to a peristaltic pump. Finally, the roof contains essential residues, offering therapeutic options to block ABCG2 by either targeting the valve or essential residues in the roof.
Keyphrases
- aortic valve
- mitral valve
- aortic stenosis
- drug release
- cancer stem cells
- transcatheter aortic valve replacement
- endothelial cells
- drug delivery
- ejection fraction
- left ventricular
- heart failure
- emergency department
- coronary artery disease
- cystic fibrosis
- high resolution
- staphylococcus aureus
- pseudomonas aeruginosa
- transcription factor
- atrial fibrillation
- binding protein
- candida albicans